INmune Bio (NASDAQ:INMB - Get Free Report)'s stock had its "sell (e+)" rating reissued by investment analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.
A number of other equities analysts have also recently commented on INMB. Scotiabank reaffirmed a "sector underperform" rating on shares of INmune Bio in a report on Tuesday, July 1st. Wall Street Zen cut shares of INmune Bio from a "hold" rating to a "sell" rating in a report on Saturday, August 2nd. BTIG Research reaffirmed a "neutral" rating on shares of INmune Bio in a report on Tuesday, July 1st. Raymond James Financial cut shares of INmune Bio from a "moderate buy" rating to a "hold" rating in a report on Monday, June 30th. Finally, Maxim Group cut their target price on shares of INmune Bio from $30.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $18.50.
View Our Latest Stock Analysis on INMB
INmune Bio Trading Up 2.6%
Shares of INmune Bio stock opened at $2.01 on Wednesday. The company has a fifty day simple moving average of $2.19 and a 200-day simple moving average of $4.85. INmune Bio has a 12-month low of $1.71 and a 12-month high of $11.64. The stock has a market cap of $53.43 million, a price-to-earnings ratio of -0.81 and a beta of 1.04.
INmune Bio (NASDAQ:INMB - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.03. On average, analysts forecast that INmune Bio will post -2.24 earnings per share for the current fiscal year.
Institutional Investors Weigh In On INmune Bio
Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of INmune Bio by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 389,931 shares of the company's stock worth $901,000 after purchasing an additional 25,069 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of INmune Bio by 240.9% in the 2nd quarter. XTX Topco Ltd now owns 125,847 shares of the company's stock worth $291,000 after acquiring an additional 88,928 shares during the period. MAI Capital Management increased its stake in INmune Bio by 6.0% in the 1st quarter. MAI Capital Management now owns 106,797 shares of the company's stock valued at $834,000 after purchasing an additional 6,030 shares in the last quarter. Pekin Hardy Strauss Inc. raised its holdings in INmune Bio by 13.1% during the first quarter. Pekin Hardy Strauss Inc. now owns 94,300 shares of the company's stock worth $736,000 after purchasing an additional 10,950 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in INmune Bio by 1,042.7% during the second quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company's stock worth $169,000 after purchasing an additional 66,700 shares in the last quarter. 12.72% of the stock is currently owned by hedge funds and other institutional investors.
INmune Bio Company Profile
(
Get Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
